Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected
Comparing 2 of 2 drugs
× ×
Change selection
2 drug columns · use arrows or scrollbar
Field TICAGRELOR
Haematology · Haematology · Level 2
 ABCIXIMAB
Haematology · Haematology · Level 3
Mechanism of action

Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking

Similar mechanism as tirofiban but monoclonal
antibody
Absorption

BA=40%

 —
Metabolism

Metabolized by CYP3A4

Platelet function
typically returns to
normal 24-48 hours after
infusion ceases
Excretion —

Platelet function
typically returns to
normal 24-48 hours after
infusion ceases
Adverse Effects Toxicity —

Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction
Class Group

Antiplatelet

Antiplatelet
Introduction

ADP Receptor Antagonist - Thienopyridine

GP IIb/IIIA Inhibitor
Legacy Cicm Level

Level 3

Level 3
Main Action

Platelet inhibition

Platelet inhibition